Next Article in Journal
Sustaining Vaccine Confidence in the 21st Century
Next Article in Special Issue
The Potential Impact of Preventive HIV Vaccines in China: Results and Benefits of a Multi-Province Modeling Collaboration
Previous Article in Journal
Hepatitis B Vaccination in Pregnancy in the United States
Previous Article in Special Issue
Factors Affecting the Acceptance of Pandemic Influenza A H1N1 Vaccine amongst Essential Service Providers: A Cross Sectional Study
Vaccines 2013, 1(2), 174-203; doi:10.3390/vaccines1020174
Review

Tumor-Associated Glycans and Immune Surveillance

1, 2 and 1,*
1 Winthrop P. Rockefeller Cancer Institute and Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA 2 Stephan Angeloff Institute of Microbiology, BAS, Sofia 1113, Bulgaria
* Author to whom correspondence should be addressed.
Received: 18 April 2013 / Revised: 18 April 2013 / Accepted: 6 June 2013 / Published: 17 June 2013
(This article belongs to the Special Issue Feature Papers)
View Full-Text   |   Download PDF [680 KB, uploaded 17 June 2013]   |  

Abstract

Changes in cell surface glycosylation are a hallmark of the transition from normal to inflamed and neoplastic tissue. Tumor-associated carbohydrate antigens (TACAs) challenge our understanding of immune tolerance, while functioning as immune targets that bridge innate immune surveillance and adaptive antitumor immunity in clinical applications. T-cells, being a part of the adaptive immune response, are the most popular component of the immune system considered for targeting tumor cells. However, for TACAs, T-cells take a back seat to antibodies and natural killer cells as first-line innate defense mechanisms. Here, we briefly highlight the rationale associated with the relative importance of the immune surveillance machinery that might be applicable for developing therapeutics.
Keywords: monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate monoclonal antibodies; immunotherapy; cancer; mimics; vaccine; TACA; glycans; tumor; carbohydrate
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Monzavi-Karbassi, B.; Pashov, A.; Kieber-Emmons, T. Tumor-Associated Glycans and Immune Surveillance. Vaccines 2013, 1, 174-203.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert